Research and InnovationArticle
From Brexanolone to Psychedelics: The New Frontier of Psychiatric Pharmacotherapy
After decades of modest advances in psychopharmacology, psychiatry is finally entering a new era — marked not by incremental adjustments...
By João L. de Quevedo, MD, PhD
Published on · Last reviewed on · 4 min read
In this article
After decades of modest advances in psychopharmacology, psychiatry is finally entering a new era — marked not by incremental adjustments to serotonin pathways, but by bold forays into previously unexplored neurobiological territory. New agents, such as brexanolone — the first treatment approved by the FDA specifically for postpartum depression — and psychedelic compounds such as psilocybin and MDMA, are reshaping our understanding of what psychiatric treatment can be.
These emerging pharmacological interventions offer the promise of rapid symptom relief, novel mechanisms of action, and synergistic use with psychotherapeutic techniques. For clinicians, researchers, and — above all — patients, this represents a long-awaited change in the approach to treatment-resistant depression, trauma, and mood disorders.
Brexanolone and the Neurosteroid Revolution
Approved in 2019, brexanolone is a synthetic formulation of allopregnanolone, a neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors. Its mechanism differs from that of traditional antidepressants, targeting the brain’s inhibitory system rather than monoaminergic pathways.
Administered as a 60-hour intravenous infusion, brexanolone has demonstrated rapid and robust improvements in postpartum depression, sometimes within 48 hours. This contrasts sharply with conventional antidepressants, which can take weeks to work and are often less effective in postpartum populations.
Despite its potential, brexanolone faces practical challenges: a lengthy infusion, high cost, and the need for hospital monitoring. Fortunately, zuranolone — an oral analogue with a similar mechanism — was recently approved for major depressive disorder and postpartum depression, offering patients a more accessible option.
These agents represent more than a therapeutic advance: they reflect a growing understanding of GABAergic modulation and its role in stress, mood regulation, and neuroplasticity.
Psychedelics: From Stigma to Science
Perhaps the most striking resurgence in psychiatric pharmacology is the scientific rehabilitation of psychedelics. Substances such as psilocybin (the active compound in “magic mushrooms”), MDMA, DMT, and LSD are being reexamined not as relics of the counterculture, but as powerful therapeutic tools with the potential to transform mental health care.
The mechanism of action of these compounds generally involves 5-HT2A receptor agonism, which promotes the disruption of rigid neural networks, increases connectivity, and facilitates rapid changes in neuroplasticity. In particular, psilocybin has been shown to reduce activity in the default mode network — a set of brain regions associated with self-referential thinking and rumination, central features of depression.
Recent clinical trials are encouraging:
- Psilocybin has shown sustained antidepressant effects after just one or two sessions, especially in patients with treatment-resistant depression.
- MDMA, combined with psychotherapy, has demonstrated remarkable efficacy in PTSD, achieving remission in up to 67% of participants in Phase III trials.
- Both compounds have received Breakthrough Therapy designation from the FDA, highlighting their potential for accelerated approval if results continue to support their efficacy and safety.
Clinical and Ethical Considerations
Although these pharmacological innovations are encouraging, they also bring clinical, logistical, and ethical challenges:
- Set and setting matter greatly: psychedelic experiences are profoundly influenced by the environment and the clinician’s guidance. This has led to the development of psychedelic-assisted therapy models, which require specialized training.
- Access and equity must be considered: high costs and geographical limitations may exacerbate inequalities in mental health care.
- Long-term safety is still under investigation: although most trials show favorable side-effect profiles, more data are still needed on the durability and reproducibility of results.
- Regulatory barriers persist: for example, brexanolone requires a REMS (Risk Evaluation and Mitigation Strategy) program, and psychedelics remain classified as Schedule I substances under federal law.
As these treatments move closer to mainstream clinical practice, careful implementation strategies will be crucial.
Looking Ahead
We are entering a pharmacological era informed by neurocircuitry, aligning medication strategies with neurobiological targets in ways that previous treatments could not. The future may include:
- Combination therapies that bring together psychedelics or neurosteroids with psychotherapy, neuromodulation, or digital interventions.
- Biomarker-based personalization, using pharmacogenomics and neuroimaging to guide treatment selection.
- Expansion of clinical trial networks, including academic centers such as UTHealth Houston, to validate these approaches in real-world settings.
Although caution and rigorous science must guide our next steps, this moment represents a rare turning point in psychiatry — full of hope, innovation, and the possibility of transforming lives.
By Joao L. de Quevedo, MD, PhD. Director of the Center for Interventional Psychiatry, UTHealth Houston
References
- Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 2022; 387:1637–1648. https://doi.org/10.1056/NEJMoa2206443 · doi:10.1056/NEJMoa2206443
- Meltzer-Brody S, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018. · doi:10.1016/S0140-6736(18)31551-4
- Deligiannidis KM, et al. Zuranolone for the treatment of postpartum depression. Am J Psychiatry. 2023. · doi:10.1176/appi.ajp.20220785
- Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021. · doi:10.1038/s41591-021-01336-3
Related content
Mood Disorders
Celebrating 75 Years Since the Discovery of Lithium
Discovered by Swedish chemist Johan August Arfwedson in 1817, lithium's potential truly began to unfold on May 5,...
· Article
Mood Disorders
Understanding the complexity of catatonia
Catatonia, a perplexing neuropsychiatric condition, often remains poorly understood despite its profound impact on...
· Explainer
Mood Disorders
What is bipolar disorder?
Bipolar disorder, also known as manic-depressive illness, is a psychiatric condition that causes unusual changes in mood...
· Explainer